CD27 Monoclonal Antibody (LG.7F9), FITC, eBioscience™, Invitrogen™

Description

• Description: The LG.7F9 monoclonal antibody reacts with mouse CD27, a lymphocyte-specific member of the TNFR superfamily
• CD27 is expressed by virtually all mature T cells and by a subpopulation of B cells, mainly memory B cells
• In mouse, CD27 has been found on nearly all thymocytes excluding a population of CD46-CD8- precursors
• CD27 binds to CD70 and, through this interaction, plays an important role in T cell-B cell interaction
• It has been reported that triggering CD27 plays an important role in the maturation of CD4+ and CD8+ effector cells
• LG.7F9 cross-reacts with human and rat CD27
• Applications Reported: The LG.7F9 antibody has been reported for use in flow cytometric analysis
• Applications Tested: The LG.7F9 antibody has been tested by flow cytometric analysis of mouse splenocytes
• This can be used at less than or equal to 0.5 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Excitation: 488 nm; Emission: 520 nm; Laser: Blue Laser
• Filtration: 0.2 μm post-manufacturing filtered
• CD27 is a 50 kDa member of the tumor necrosis factor (TNF) receptor superfamily that includes CD40 and CD30
• The TNF superfamily members are known for the regulation of cell proliferation and death
• In contrast to the expression of other TNFR/TNF family members, expression of CD27 and its ligand CD70 is predominantly confined to lymphocytes
• High expression levels of CD27 appear to be dependent on proper ligation of antigen receptors
• CD70 expression requires additional co-stimulatory and/or pro-inflammatory signals
• CD27 is expressed as a disulfide-linked homodimer on mature thymocytes, peripheral blood T cells and a subpopulation of B cells
• Activation of T cells via TCR-CD3 complex results in upregulation of CD27 expression on the plasma membrane as well as in the release of its soluble 28-32 kDa form, sCD27, detected in the plasma, urine or spinal fluid
• Soluble CD27 is an important prognostic marker of acute and chronic B cell malignancies
• RgpA, a cystein proteinase, although activating T cells through the protease-activated receptors (PARs), degradates CD27 and counteracts T cell activation mediated by CD27 and its ligand CD70
• CD27-binding protein (SIVA), a proapoptotic protein, can bind to this receptor and is thought to play an important role in the apoptosis induced by this receptor
• Diseases associated with CD27 dysfunction include Lymphoproliferative Syndrome 2 and Autosomal Recessive Lymphoproliferative Syndrome.